Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

Big pharma goes shopping as "patent cliff" puts more than $225 billion in revenues at risk.

Related Keywords

Evan David Seigerman ,William Blair ,Stephen Morehouse ,Horizon Therapeutics ,Amgen Inc ,Microsoft Corp ,Activision Blizzard Inc ,Abbvie Inc ,While The Federal Trade Commission ,Pfizer ,Eli Lilly Co ,Amgen ,Federal Trade Commission ,Eli Lilly ,Evaluate Pharma ,Inflation Reduction Act ,Activision Blizzard ,Article Normal ,Humira ,Fattyliverdisease ,Nash ,Bigpharma ,Patentcliff ,Medicare ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Biopharmaceuticals ,Regulation Government Policy ,Patents ,Ownership Changes ,Acquisitions Mergers Shareholdings ,Anti Competition Issues ,Acquisitions Mergers ,Corporate Actions ,Corporate Industrial News ,Intellectual Property Rights ,Industrial Property Rights ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Regulation ,Government Policy ,Acquisitions ,Mergers ,Shareholdings ,Corporate ,Industrial News ,Healthcare ,Life Sciences ,